Jodar E - Search Results

1

[The risk factors and bone mineral density in women on long-term levothyroxine treatment].

López Alvarez MB, Hawkins F, Rigopoulou D, Martínez G, Jodar E, Estenoz J, Ortuño B, Arnaiz F. López Alvarez MB, et al. Among authors: jodar e. Med Clin (Barc). 1999 Jan 30;112(3):85-9. Med Clin (Barc). 1999. PMID: 10074614 Spanish.

2

Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.

Jódar E, Begoña López M, García L, Rigopoulou D, Martínez G, Hawkins F. Jódar E, et al. Osteoporos Int. 1998;8(4):311-6. doi: 10.1007/s001980050069. Osteoporos Int. 1998. PMID: 10024900

3

Long-term follow-up of bone mineral density in Addison's disease.

Jódar E, Valdepeñas MP, Martinez G, Jara A, Hawkins F. Jódar E, et al. Clin Endocrinol (Oxf). 2003 May;58(5):617-20. doi: 10.1046/j.1365-2265.2003.01761.x. Clin Endocrinol (Oxf). 2003. PMID: 12699444

4

Bone mineral density in children and adolescents with diabetes mellitus type 1 of recent onset.

Pascual J, Argente J, Lopez MB, Muñoz M, Martinez G, Vazquez MA, Jodar E, Perez-Cano R, Hawkins F. Pascual J, et al. Among authors: jodar e. Calcif Tissue Int. 1998 Jan;62(1):31-5. doi: 10.1007/s002239900390. Calcif Tissue Int. 1998. PMID: 9405730

5

Bone mineral density in male patients with L-thyroxine suppressive therapy and Graves disease.

Jódar E, Martínez-Díaz-Guerra G, Azriel S, Hawkins F. Jódar E, et al. Calcif Tissue Int. 2001 Aug;69(2):84-7. doi: 10.1007/s002230020041. Calcif Tissue Int. 2001. PMID: 11683428

6

Bone mass after long-term euthyroidism in former hyperthyroid women treated with (131)I influence of menopausal status.

Serraclara A, Jódar E, Sarabia F, Hawkins F. Serraclara A, et al. Among authors: jodar e. J Clin Densitom. 2001 Fall;4(3):249-55. doi: 10.1385/jcd:4:3:249. J Clin Densitom. 2001. PMID: 11740067

7

Bone mineral density in hypoparathyroid women on LT4 suppressive therapy. Effect of calcium and 1,25(OH)2 vitamin D3 treatment.

Hawkins F, Escobar-Jiménez F, Jódar E, Campos MM, López Alvarez MB, Martínez Díaz-Guerra G. Hawkins F, et al. Among authors: jodar e. J Musculoskelet Neuronal Interact. 2003 Mar;3(1):71-6. J Musculoskelet Neuronal Interact. 2003. PMID: 15758368 Free article.

8

Bone loss after heart transplant: effect of alendronate, etidronate, calcitonin, and calcium plus vitamin D3.

Gilfraguas L, Guadalix S, Martinez G, Jodar E, Vara J, Gomez-Sanchez MA, Delgado J, De La Cruz J, Lora D, Hawkins F. Gilfraguas L, et al. Among authors: jodar e. Prog Transplant. 2012 Sep;22(3):237-43. doi: 10.7182/pit2012969. Prog Transplant. 2012. PMID: 22951500 Clinical Trial.

9

[Physiopathologic basis of obesity].

Martínez G, Jódar E, Hawkins F. Martínez G, et al. Among authors: jodar e. Aten Primaria. 2000 Apr 15;25(6):425-31. doi: 10.1016/s0212-6567(00)78535-0. Aten Primaria. 2000. PMID: 10857235 Free PMC article. Review. Spanish. No abstract available.

10

Effect of alendronate in elderly patients after low trauma hip fracture repair.

Cecilia D, Jódar E, Fernández C, Resines C, Hawkins F. Cecilia D, et al. Among authors: jodar e. Osteoporos Int. 2009 Jun;20(6):903-10. doi: 10.1007/s00198-008-0767-z. Epub 2008 Oct 28. Osteoporos Int. 2009. PMID: 18956132 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

87 results

Search Page

Filters